BCL-W makes only minor contributions to MYC-driven lymphoma development

The BH3-mimetic drug Venetoclax, a specific inhibitor of anti-apoptotic BCL-2, has had clinical success for the treatment of chronic lymphocytic leukaemia and acute myeloid leukaemia. Attention has now shifted towards related pro-survival BCL-2 family members, hypothesising that new BH3-mimetic drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Diepstraten, Sarah T., La Marca, John E., Chang, Catherine, Young, Savannah, Strasser, Andreas, Kelly, Gemma L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491490/
https://www.ncbi.nlm.nih.gov/pubmed/37567974
http://dx.doi.org/10.1038/s41388-023-02804-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491490/
https://www.ncbi.nlm.nih.gov/pubmed/37567974
http://dx.doi.org/10.1038/s41388-023-02804-5

Ejemplares similares